These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28197938)

  • 1. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
    Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
    Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.
    Chakravarty EF; Martyanov V; Fiorentino D; Wood TA; Haddon DJ; Jarrell JA; Utz PJ; Genovese MC; Whitfield ML; Chung L
    Arthritis Res Ther; 2015 Jun; 17(1):159. PubMed ID: 26071192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety Evaluation of Taohong Siwu Decoction () for Patients with Angina Pectoris: A Meta-Analysis of Randomized Controlled Trials.
    Tao TQ; Mao HM; Xia L; Liu XH
    Chin J Integr Med; 2021 Aug; 27(8):626-632. PubMed ID: 30941683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
    Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
    Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis.
    Takehara K; Ihn H; Sato S
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):151-6. PubMed ID: 23910617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.
    Postlethwaite AE; Wong WK; Clements P; Chatterjee S; Fessler BJ; Kang AH; Korn J; Mayes M; Merkel PA; Molitor JA; Moreland L; Rothfield N; Simms RW; Smith EA; Spiera R; Steen V; Warrington K; White B; Wigley F; Furst DE
    Arthritis Rheum; 2008 Jun; 58(6):1810-22. PubMed ID: 18512816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
    Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
    Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
    Denton CP; Merkel PA; Furst DE; Khanna D; Emery P; Hsu VM; Silliman N; Streisand J; Powell J; Akesson A; Coppock J; Hoogen Fv; Herrick A; Mayes MD; Veale D; Haas J; Ledbetter S; Korn JH; Black CM; Seibold JR; ;
    Arthritis Rheum; 2007 Jan; 56(1):323-33. PubMed ID: 17195236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
    Spiera RF; Gordon JK; Mersten JN; Magro CM; Mehta M; Wildman HF; Kloiber S; Kirou KA; Lyman S; Crow MK
    Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
    Valentini G; Paone C; La Montagna G; Chiarolanza I; Menegozzo M; Colutta E; Ruocco L
    Scand J Rheumatol; 2006; 35(1):35-8. PubMed ID: 16467039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy Observation of Chinese Herbal Fumigation Combined Western Drugs for Treating Sys- temic Sclerosis Complicated Pulmonary Arterial Hypertension].
    Zhou J; Yang D; Zhou SH; Wang JP; Lu Y; Wang HJ; Zhang JH; Lei SW
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Aug; 36(8):933-937. PubMed ID: 30640987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
    Gordon JK; Martyanov V; Franks JM; Bernstein EJ; Szymonifka J; Magro C; Wildman HF; Wood TA; Whitfield ML; Spiera RF
    Arthritis Rheumatol; 2018 Feb; 70(2):308-316. PubMed ID: 29073351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.
    Khanna D; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; de Oliveira Pena J; Yao Z; Kramer F; Distler O
    Ann Rheum Dis; 2020 May; 79(5):618-625. PubMed ID: 32299845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.